Callan Capital LLC Invests $192,000 in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Callan Capital LLC acquired a new position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 13,451 shares of the company’s stock, valued at approximately $192,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Sage Rhino Capital LLC boosted its holdings in Takeda Pharmaceutical by 7.6% in the third quarter. Sage Rhino Capital LLC now owns 11,751 shares of the company’s stock valued at $182,000 after purchasing an additional 831 shares in the last quarter. Legacy Wealth Asset Management LLC lifted its stake in Takeda Pharmaceutical by 0.7% in the third quarter. Legacy Wealth Asset Management LLC now owns 124,967 shares of the company’s stock valued at $1,933,000 after buying an additional 851 shares during the last quarter. Vestmark Advisory Solutions Inc. lifted its stake in Takeda Pharmaceutical by 1.4% in the third quarter. Vestmark Advisory Solutions Inc. now owns 63,630 shares of the company’s stock valued at $984,000 after buying an additional 870 shares during the last quarter. Cambridge Investment Research Advisors Inc. lifted its stake in Takeda Pharmaceutical by 5.7% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 16,433 shares of the company’s stock valued at $254,000 after buying an additional 883 shares during the last quarter. Finally, Simplicity Solutions LLC lifted its stake in Takeda Pharmaceutical by 0.4% in the third quarter. Simplicity Solutions LLC now owns 213,515 shares of the company’s stock valued at $3,303,000 after buying an additional 955 shares during the last quarter. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Stock Performance

NYSE TAK traded down $0.04 on Friday, reaching $13.03. The stock had a trading volume of 1,213,476 shares, compared to its average volume of 1,688,482. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.55 and a current ratio of 1.06. Takeda Pharmaceutical Company Limited has a 12-month low of $13.01 and a 12-month high of $17.11. The business’s 50-day moving average price is $14.06 and its 200 day moving average price is $14.20. The stock has a market cap of $41.24 billion, a P/E ratio of 19.75, a price-to-earnings-growth ratio of 2.98 and a beta of 0.53.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings results on Thursday, February 1st. The company reported $0.51 EPS for the quarter. Takeda Pharmaceutical had a return on equity of 12.57% and a net margin of 6.90%. The business had revenue of $7.52 billion during the quarter. As a group, equities analysts expect that Takeda Pharmaceutical Company Limited will post 1.5 earnings per share for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.